Ignite Creation Date:
2024-05-06 @ 8:01 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06229184
Status:
COMPLETED
Last Update Posted:
2024-02-13
First Post:
2024-01-09
Brief Title:
Can Fecal Calprotectin Be Used as a Biomarker of Non-alcoholic Fatty Liver Disease In Obese Adolescents
Sponsor:
Sisli Hamidiye Etfal Training and Research Hospital
Organization:
Sisli Hamidiye Etfal Training and Research Hospital
Study Overview
Official Title:
Can Fecal Calprotectin Be Used as a Biomarker of Non-alcoholic Fatty Liver Disease In Obese Adolescents
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The incidence of non-alcoholic fatty liver disease NAFLD is increasing with obesity and it is believed that ongoing inflammation in obesity and alterations in the enterohepatic axis contribute to this process This study aimed to determine the role of fecal calprotectin FCP as an inflammatory biomarker in course of obesity and NAFLD
Detailed Description:
Obesity is a significant public health issue worldwide With the increasing prevalence of obesity the prevalence of metabolic syndrome in adolescents is also on the rise Non-alcoholic fatty liver disease NAFLD a major cause of chronic liver disease is the hepatic component of metabolic syndrome The prevalence of NAFLD is not precisely known but in some studies it is between 225 and 528 in children with obesity constituting 26 of all children Although the mechanisms involved in the development of obesity-related metabolic complications and NAFLD are not well understood it is believed that intestinal inflammation changes in the microbiota and alterations in the gut-liver axis GLA may play a role in the development of low-grade chronic inflammation in NAFLD associated with obesity Fecal calprotectin FCP which has become increasingly important in demonstrating intestinal inflammation in recent years is a widely used test particularly in the diagnosis and monitoring of inflammatory bowel disease and various gastrointestinal disorders In our study the utility of FCP as an inflammatory biomarker in the course of NAFLD in obese adolescents has been investigated The study was approved by our hospitals ethics committee in 15112022 and another ethics committee approval was taken in 08062023 for title change of study This study conducted under the Helsinki Declaration
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None